

## DAFTAR PUSTAKA

- Aboktifa, M. A., & Abbas, D. A. (2020). Interaction Toxicity Study between P-glycoprotein Inhibitor (Captopril) and Inducer (Spironolactone) with Their Substrate (Lovastatin) in Male Rats. *The Iraqi Journal of Veterinary Medicine*, 44((E0)), 106–112. [https://doi.org/10.30539/ijvm.v44i\(e0\).1032](https://doi.org/10.30539/ijvm.v44i(e0).1032)
- Acosta, E. P. (2018). Antiviral Agents (Nonretroviral). In *Goodman & Gilman's: The Pharmacological Basic of Therapies* (13th ed., pp. 1105–1116). McGraw-Hill Medical.
- Akhmerov, A., & Marbán, E. (2020). COVID-19 and the Heart. In *Circulation Research* (pp. 1443–1455). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIRCRESAHA.120.317055>
- Ambrus, C., Bakos, É., Sarkadi, B., Özvegy-Laczka, C., & Telbisz, Á. (2021). Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. *Scientific Reports*, 11(1). <https://doi.org/10.1038/s41598-021-97160-3>
- Anonim. (2022). *Update COVID-19 Banyumas-Pemkab Banyumas. Banyumas Tanggap COVID-19.* <http://covid19.banyumaskab.go.id/> diakses pada 16 Juni 2022.
- Aras-Atik, E., Tecen-Yucel, K., & Bayraktar-Ekincioglu, A. (2020). Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19? In *Journal of Oncology Pharmacy Practice* (Vol. 26, Issue 7, pp. 1807–1817). SAGE Publications Ltd. <https://doi.org/10.1177/1078155220935506>
- Asadi-Pooya, A. A., Attar, A., Moghadami, M., & Karimzadeh, I. (2020). Management of COVID-19 in people with epilepsy: drug considerations. *Neurological Sciences* (2020) 41:2005–2011. <https://doi.org/10.1007/s10072-020-04549-5/Published>
- Awortwe, C., & Cascorbi, I. (2020). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information . January.

- Azer, S. A. (2020). COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. *New Microbes and New Infections*, 100738.
- Backman, J. T., Filppula, A. M., Niemi, M., & Neuvonen, P. J. (2016). Role of Cytochrome P450 2C8 in drug metabolism and interactions. *Pharmacological Reviews*, 68(1), 168–241. <https://doi.org/10.1124/pr.115.011411>
- Badan Pengawasan Obat dan Makanan Republik Indonesia. (2015). *Lampiran 1: Interaksi Obat*. <http://pionas.pom.go.id/ioni/lampiran-1-interaksi-obat-0>
- Badan Pengawasan Obat dan Makanan Republik Indonesia. (2020). *Informatorium obat Covid*.
- Bahap, M., Kara, E., & Guven, G. S. (2021). Fighting on two fronts: drug–drug interactions in people living with HIV infected with SARS-CoV-2. *European Journal of Hospital Pharmacy*, 28(1), e3-e3.
- Bwire, G. M. (n.d.). *Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women?* <https://doi.org/10.1007/s42399-020-00341-w/Published>
- Cai, H. (2020). Sex difference and smoking predisposition in patients with COVID-19. *The Lancet Respiratory Medicine*, 8(4), e20.
- Cantudo-Cuenca, M. D., Gutiérrez-Pizarraya, A., Pinilla-Fernández, A., Contreras-Macías, E., Fernández-Fuertes, M., Lao-Domínguez, F. A., Rincón, P., Pineda, J. A., Macías, J., & Morillo-Verdugo, R. (2021). Drug–drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. *Scientific Reports*, 11(1). <https://doi.org/10.1038/s41598-021-91953-2>
- Carpenter, A., Chambers, O. J., El Harchi, A., Bond, R., Hanington, O., Harmer, S. C., ... & James, A. F. (2020). COVID-19 management and arrhythmia: risks and challenges for clinicians treating patients affected by SARS-CoV-2. *Frontiers in Cardiovascular Medicine*, 7, 85.
- Cattaneo, D., Pasina, L., Conti, F., Giacomelli, A., Oreni, L., Pezzati, L., Bonazzetti, C., Piscaglia, M., Carrozzo, G., Antinori, S., & Gervasoni, C. (2021). Risks of potential drug–drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience. *Journal of*

- Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., & Lu, M. (2021). Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. *Frontiers in Pharmacology*, 2292.
- Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Zhang, J., & Wang, X. (2020). Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. *MedRxiv*. <https://doi.org/10.1101/2020.03.17.20037432>
- Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet*, 395(10223), 507–513. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
- Chiba, S. (2021). Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19. *Wiener Klinische Wochenschrift*, 133(7–8), 292–297. <https://doi.org/10.1007/s00508-020-01780-0>
- Chicago, L. & Baxter Bsc, K. (2010). *Stockley's Drug Interactions Ninth Edition*. Chicago: Pharmaceutical Press.
- Chinello, P., Petrosillo, N., Pittalis, S., Biava, G., Ippolito, G., & Nicastri, E. (2017). QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. *PLoS Neglected Tropical Diseases*, 11(12), e0006034. <https://doi.org/10.1371/journal.pntd.0006034>
- Coenen, S., van Der Velden, A. W., Cianci, D., Goossens, H., Bongard, E., Saville, B. R., Gobat, N., de Paor, M., Ieven, M., & Verheij, T. J. (2020). Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018. *British Journal of General Practice*, 70(696), e444–e449.

- Colunga Biancatelli, R. M. L., Congedo, V., Calvosa, L., Ciacciarelli, M., Polidoro, A., & Iuliano, L. (2019). Adverse reactions of amiodarone. In *Journal of Geriatric Cardiology* (Vol. 16, Issue 7, pp. 552–566). Science Press. <https://doi.org/10.11909/j.issn.1671-5411.2019.07.004>
- Corcoran, C., & Jacobs, TF. (2022). *Metformin*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK518983/>
- David, MNV., & Shetty, M. (2022). *Digoxin*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK556025/>
- Day, L. B., Abdel-Qadir, H., & Fralick, M. (2021). Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man. *CMAJ*, 193(17), E612–E615. <https://doi.org/10.1503/cmaj.210300>
- Demir, E., Sütcüoğlu, O., Demir, B., Ünsal, O., & Yazıcı, O. (2021). A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma. *Journal of Oncology Pharmacy Practice*, 10781552211031304.
- Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020). Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. *International Journal of Environmental Research and Public Health*, 17(8). <https://doi.org/10.3390/ijerph17082690>
- Dou, D., Revol, R., Östbye, H., Wang, H., & Daniels, R. (2018). Influenza A virus cell entry, replication, virion assembly and movement. *Frontiers in Immunology*, 9(JUL), 1–17. <https://doi.org/10.3389/fimmu.2018.01581>
- Drug Bank. (2022). *Drug Information*. <https://go.drugbank.com/drugs>
- Du, Y. X., & Chen, X. P. (2020). Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. In *Clinical Pharmacology and Therapeutics* (Vol. 108, Issue 2, pp. 242–247). Nature Publishing Group. <https://doi.org/10.1002/cpt.1844>
- Duan, P., Li, S., Ai, N., Hu, L., Welsh, W. J., & You, G. (2012). Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: Discovery and molecular characterization. *Molecular Pharmaceutics*, 9(11), 3340–3346. <https://doi.org/10.1021/mp300365t>

- Ejaz, H., Alsrhani, A., Zafar, A., Javed, H., Junaid, K., Abdalla, A. E., Abosalif, K. O. A., Ahmed, Z., & Younas, S. (2020). COVID-19 and comorbidities: Deleterious impact on infected patients. In *Journal of Infection and Public Health* (Vol. 13, Issue 12, pp. 1833–1839). Elsevier Ltd. <https://doi.org/10.1016/j.jiph.2020.07.014>
- Elmeliogy, M., Vourvahis, M., Guo, C., & Wang, D. D. (2020). Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug–drug interaction studies. *Clinical Pharmacokinetics*, 59(6), 699–714.
- Elviani, R., Anwar, C., & Sitorus, R. J. (2021). Gambaran usia pada kejadian Covid-19. *JAMBI MEDICAL JOURNAL" Jurnal Kedokteran Dan Kesehatan"*, 9(2), 204–209.
- Ershad, M., Naji, A., & Vearrier, D. (2022). *N Acetylcysteine*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK537183/>
- Fadaka, A. O., Sibuyi, N. R. S., Adewale, O. B., Bakare, O. O., Akanbi, M. O., Klein, A., Madiehe, A. M., & Meyer, M. (2020). Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. *Journal of International Medical Research*, 48(8). <https://doi.org/10.1177/0300060520949077>
- Fadare, J., Ajayi, A., Adeoti, A., Desalu, O., Obimakinde, A., & Agboola, S. (2016). Potential drug-drug interactions among elderly patients on anti-hypertensive medications in two tertiary healthcare facilities in Ekiti State, South-West Nigeria. *Sahel Medical Journal*, 19(1), 32. <https://doi.org/10.4103/1118-8561.181896>
- Fatimah, V. A. N., Istiqomah, N. S., & Fadjri, M. (2021). C95. The electrocardiographic changes in a hypertensive COVID-19 patient who received beta-blocker and favipiravir: a case report. *European Heart Journal Supplements*, 23(Supplement\_F), suab124-094.
- FDA. (2016). *Imodium Capsule RX*. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/017694s052lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017694s052lbl.pdf)

- FDA. (2018). *Cordarone Highlights of Prescribing Information*.  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/018972s054lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018972s054lbl.pdf)
- Finch, A., & Pillans, P. (2014). P-glycoprotein and its role in drug-drug interactions. *Aust Prescr*, 37(4), 137–139.
- Firat, O., Çakır, B. K., & Demirkhan, K. (2020). *Drug-drug Interactions of Antithrombotic Medications During Treatment of COVID-19*.
- Gandhi, Z., Mansuri, Z., & Bansod, S. (n.d.). *Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective*.  
<https://doi.org/10.1007/s42399-020-00462-2/Published>
- Garrison, D. A., Talebi, Z., Eisenmann, E. D., Sparreboom, A., & Baker, S. D. (2020). Role of oatp1b1 and oatp1b3 in drug-drug interactions mediated by tyrosine kinase inhibitors. In *Pharmaceutics* (Vol. 12, Issue 9, pp. 1–18). MDPI AG. <https://doi.org/10.3390/pharmaceutics12090856>
- George, TT., & Tripp, J. (2022). *Alprazolam*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK538165/>
- Ghlichloo, I., & Gerriets, V. (2022). *Nonsteroidal Anti-inflammatory Drugs (NSAIDs)*. Treasure Island (FL): StatPearls Publishing.  
<https://www.ncbi.nlm.nih.gov/books/NBK547742/>
- Gómez-Moreno, G. (2020). Remdesivir-COVID-19: Drug interactions in dentistry. *European Review for Medical and Pharmacological Sciences*, 24(18), 9739–9743. [https://doi.org/10.26355/eurrev\\_202009\\_23065](https://doi.org/10.26355/eurrev_202009_23065)
- Haghjoo, M., Golipra, R., Kheirkhah, J., Golabchi, A., Shahabi, J., Oni-Heris, S., Sami, R., Tajmirriahi, M., Saravi, M., & Khatami, M. (2021). Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey. *International Journal of Clinical Practice*, 75(7), e14182.
- Hamid, S., Mir, M. Y., & Rohela, G. K. (2020). Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). *New Microbes and New Infections*, 35, 100679.

- Hasanah, D. Y., Nauli, S. E., Prima Putri, V. K., Arifianto, H., Suryana, N. M., Suryani, L. D., Aditya, W., & Probodewi, P. (2020). Gangguan Kardiovaskular pada infeksi COVID 19. *Indones J Cardiol*, 41(2), 59–68.
- Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021). The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. *Scientific Reports*, 11(1), 1–11. <https://doi.org/10.1038/s41598-021-90551-6>
- Hendera, H. (2018). Interaksi Antar Obat pada Peresepan Pasien Rawat Inap Pediatrik Rumah Sakit X dengan Menggunakan Aplikasi Medscape. *JCPS (Journal of Current Pharmaceutical Sciences)*, 1(2), 75–80.
- Herman, L., & Bashir, K. (2022). *Hydrochlorothiazide*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK430766/>
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., & Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 395(10223), 497–506.
- Humayun, MJ., Samanta, D., & Carson, RP. (2022). *Clobazam*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK541043/>
- Instiaty, Sri Darmayani, I. G. A. A. P., Marzuki, J. E., Angelia, F., William, Siane, A., Sary, L. D., Yohanes, L., Widystuti, R., Nova, R., Simorangkir, D. S., Lonah, Safitri, Y., Aliska, G., & Gayatri, A. (2020a). Antiviral treatment of covid-19: A clinical pharmacology narrative review. *Medical Journal of Indonesia*, 29(3), 332–345. <https://doi.org/10.13181/mji.rev.204652>
- Instiaty, Sri Darmayani, I. G. A. A. P., Marzuki, J. E., Angelia, F., William, Siane, A., Sary, L. D., Yohanes, L., Widystuti, R., Nova, R., Simorangkir, D. S., Lonah, Safitri, Y., Aliska, G., & Gayatri, A. (2020b). Antiviral treatment of covid-19: A clinical pharmacology narrative review. In *Medical Journal of Indonesia* (Vol. 29, Issue 3, pp. 332–345). Faculty of Medicine, Universitas Indonesia. <https://doi.org/10.13181/mji.rev.204652>

- Isola, S., Hussain, A., Dua, A., Singh, K., & Adams, N. (2022). *Metoclopramide*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK519517/>
- Janaszkiewicz, A., Tóth, Á., Faucher, Q., Martin, M., Chantemargue, B., Barin-Le Guellec, C., Marquet, P., & Meo, F. di. (n.d.). *Insights into the structure and function of the human organic anion transporter 1 in lipid bilayer membranes*. <https://doi.org/10.1101/2022.01.10.475390>
- Johnson, D., Lopez, M., & Kelley, B. (2022). *Dexamethasone*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK482130/?report=classic>
- Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021). Role of favipiravir in the treatment of COVID-19. *International Journal of Infectious Diseases*, 102, 501–508. <https://doi.org/10.1016/j.ijid.2020.10.069>
- Kario, K., Morisawa, Y., Sukonthasarn, A., Turana, Y., Chia, Y. C., Park, S., Wang, T. D., Chen, C. H., Tay, J. C., Li, Y., & Wang, J. G. (2020). COVID-19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network. In *Journal of Clinical Hypertension* (Vol. 22, Issue 7, pp. 1109–1119). Blackwell Publishing Inc. <https://doi.org/10.1111/jch.13917>
- Kemenkes. (2020). *KEPUTUSAN MENTERI KESEHATAN REPUBLIK INDONESIA*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kemenkes RI, 2018, Riset Kesehatan Dasar 2018, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Khan, KM., Patel, JB., & Schaefer, TJ. (2022). *Nifedipine*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK537052/>
- Kim, S. Y., & Moon, A. (2012). Drug-induced nephrotoxicity and its biomarkers. In *Biomolecules and Therapeutics* (Vol. 20, Issue 3, pp. 268–272). <https://doi.org/10.4062/biomolther.2012.20.3.268>
- (KPCPEN), K. P. C.-19 dan P. E. N. (2022). *Data Sebaran COVID-19*. <https://covid19.go.id/> diakses 16 Juni 2022.

- Kudaravalli, P., & John, S. (2022). *Sucralfate*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK551527/>
- Kumar, D., & Trivedi, N. (2021). Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. In *Biomedicine and Pharmacotherapy* (Vol. 139). Elsevier Masson s.r.l. <https://doi.org/10.1016/j.biopha.2021.111642>
- Kusumawardani, L. A., Maria, N., & Fanani, Y. N. (2021). Potential drug interactions analysis of COVID-19 patients at a hospital in West Java Analisis potensi interaksi obat pada pasien rawat inap COVID-19 pada suatu rumah sakit di Jawa Barat. *Jurnal Ilmiah Farmasi (Scientific Journal of Pharmacy)*, 17(2), 181–196. <http://journal.uii.ac.id/index.php/JIF>
- Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *International Journal of Antimicrobial Agents*, 55(3), 105924.
- Lexicomp. (2022). St. Louis: Wolters Kluwer. <https://www.uptodate.com/contents/search>
- Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., & Liu, X. (2020). Coronavirus infections and immune responses. *Journal of Medical Virology*, 92(4), 424–432.
- Li, Y., Zhou, W., Yang, L., & You, R. (2020). Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. In *Pharmacological Research* (Vol. 157). Academic Press. <https://doi.org/10.1016/j.phrs.2020.104833>
- Liu, K., Fang, Y. Y., Deng, Y., Liu, W., Wang, M. F., Ma, J. P., Xiao, W., Wang, Y. N., Zhong, M. H., Li, C. H., Li, G. C., & Liu, H. G. (2020). Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chinese Medical Journal*, 133(9), 1025–1031. <https://doi.org/10.1097/CM9.0000000000000744>
- Lu, H. (2020). Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Bioscience Trends*, 14(1), 69–71.

- Lukito, J. I. (2020). Tinjauan Antivirus untuk Terapi COVID-19. *340 Cdk-286*, 47(5), PP:342.
- Maher, R. L., Hanlon, J., & Hajjar, E. R. (2014). Clinical consequences of polypharmacy in elderly. *Expert Opinion on Drug Safety*, 13(1), 57–65.
- Manabe, T., Kambayashi, D., Akatsu, H., & Kudo, K. (2021). Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. *BMC Infectious Diseases*, 21(1), 1–13. <https://doi.org/10.1186/s12879-021-06164-x>
- Maria, G. A. R., & Raharjo, S. T. (2020). Adaptasi Kelompok Usia Produktif Saat Pandemi Covid-19 Menggunakan Metode Reality Therapy. *Jurnal Kolaborasi Resolusi Konflik*, 2(2), 142–149.
- Marte, F., Sankar, P., & Cassagnol, M. (2021). *Captopril*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK535386/>
- Mathialagan, S., Piotrowski, M. A., Tess, D. A., Feng, B., Litchfield, J., & Varma, M. v. (2017). Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor approach. *Drug Metabolism and Disposition*, 45(4), 409–417.
- Merck Manuals. (2022a). *Cefazolin*. Merck Manuals. <https://www.merckmanuals.com/professional/resources/brand-names-of-some-commonly-used-drugs>
- Merck Manuals. (2022b). *Fondaparinux*. Merck Manuals. <https://www.merckmanuals.com/professional/resources/brand-names-of-some-commonly-used-drugs>
- Merck Manuals. (2022c). *Hydrocortisone (Systemic)*. Merck Manuals. <https://www.merckmanuals.com/professional/resources/brand-names-of-some-commonly-used-drugs>
- Merck Manuals. (2022d). *Lansoprazole*. Merck Manuals. <https://www.merckmanuals.com/professional/resources/brand-names-of-some-commonly-used-drugs>

Merck Manuals. (2022e). *Tramadol*. Merck Manuals.

<https://www.merckmanuals.com/professional/resources/brand-names-of-some-commonly-used-drugs>

Morgan, K. A., & Ahlawat, R. (2021). *Ranitidine*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK532989/>

Mukherjee, S., & Pahan, K. (2021). Is COVID-19 Gender-sensitive? In *Journal of Neuroimmune Pharmacology* (Vol. 16, Issue 1, pp. 38–47). Springer. <https://doi.org/10.1007/s11481-020-09974-z>

Naksuk, N., Lazar, S., & Peeraphatdit, T. B. (2020). Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. *European Heart Journal. Acute Cardiovascular Care*. <https://doi.org/10.1177/2048872620922784>

Naqvi, A., & Gerriets, V. (2021). *Cetirizine*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK549776/>

National Institute of Health (NIH). (2020). *Coronavirus Disease 2019 (COVID-19) Treatment GuidelinesInfluenza and COVID-19*. <https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatment>

NP, B. H., & Lestari, K. (2019). Identifikasi Interaksi Antar Obat Pada Resep di Apotek Kimia Farma 58 Kota Bandung. *Farmaka*, 17(2), 57–64.

Nuryati. (2017). *Farmakologi*. Kementerian Kesehatan Republik Indonesia.

ÖZTÜRK, T., ÇAVUŞOĞLU, T., İNCİR, C., & TUNÇOK, Y. (2021). COVID-19 da Sitokinler ve COVID- 19 Tedavisinde Kullanılan İlaçlar Arasında Potansiyel İlaç Etkileşimleri. *Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi*. <https://doi.org/10.34087/cbusbed.873082>

Parohan, M., Yaghoubi, S., Seraji, A., Javanbakht, M. H., Sarraf, P., & Djalali, M. (2020). Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. *The Aging Male*, 23(5), 1416-1424.

Patel, RS., & Parmar, M. (2022). *Doxycycline Hyclate*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK555888/>

- Patibandla, S., Heaton, J., & Kyaw, H. (2022). *Spironolactone*. Treasure Island (FL): StatPearls Publishing.  
<https://www.ncbi.nlm.nih.gov/books/NBK554421/>
- PDPI. (2020). Panduan Praktik Klinis: Pneumonia COVID-19. *Journal of the American Pharmacists Association*, 55(5), 1–67.
- PDPI, PERKI, PAPDI, PERDATINI, dan I. (2021). *Revisi Protokol Tatalaksana COVID-19*.  
[https://res.cloudinary.com/dk0z4ums3/raw/upload/v1626686880/forum\\_attacc](https://res.cloudinary.com/dk0z4ums3/raw/upload/v1626686880/forum_attacc)
- Penman, S. L., Kiy, R. T., Jensen, R. L., Beoku-Betts, C., Alfirevic, A., Back, D., ... & Chadwick, A. E. (2020). Safety perspectives on presently considered drugs for the treatment of COVID-19. *British journal of pharmacology*, 177(19), 4353-4374.
- Pharmaceuticals and Medical Devices Agency. (2014). *Report on the deliberation results of favipiravir (English version)*.  
<https://www.pmda.go.jp/files/000210319.pdf>
- Plasencia-García, B. O., Rodríguez-Menéndez, G., Rico-Rangel, M. I., Rubio-García, A., Torelló-Iserte, J., & Crespo-Facorro, B. (2021). Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 14 databases and a systematic review. *Psychopharmacology*, 1–12.
- Podder, V., & Sadiq, N. M. (2022). *Levofloxacin*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK545180/>
- Qurie, A., Goyal, A., & Musa, R. (2021). *Allopurinol*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK499942/>
- Rahman, S., Singh, K., Dhingra, S., Charan, J., Sharma, P., Islam, S., Jahan, D., Iskandar, K., Samad, N., & Haque, M. (2020). The double burden of the COVID-19 pandemic and polypharmacy on geriatric population—public health implications. *Therapeutics and Clinical Risk Management*, 16, 1007.
- Rattanawong, P., Shen, W., Masry, H. el, Sorajja, D., Srivathsan, K., Valverde, A., & Scott, L. R. (2020). Guidance on short-term management of atrial fibrillation in coronavirus disease 2019. In *Journal of the American Heart*

- Association* (Vol. 9, Issue 14). American Heart Association Inc.  
<https://doi.org/10.1161/JAHA.120.017529>
- Roush, G. C., Kaur, R., & Ernst, M. E. (2014). Diuretics: A review and update. In *Journal of Cardiovascular Pharmacology and Therapeutics* (Vol. 19, Issue 1, pp. 5–13). <https://doi.org/10.1177/1074248413497257>
- Russo, A., Binetti, E., Borrazzo, C., Gentilini Cacciola, E., Battistini, L., Ceccarelli, G., Mastroianni, C. M., & d'Ettorre, G. (2021). Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: a prospective clinical experience. *Journal of Clinical Medicine*, 10(17), 3784.
- Saber-Moghaddam, N., Hejazi, S., & Elyasi, S. (2021). *Potential Drug-Drug Interactions among Hospitalized COVID-19 Patients Admitted to Medical Wards of a Referral Hospital, North-East of Iran: A Cross Sectional Study*.
- Safaa Mohammed M. Alsanosi, C. S. S. P. (2014). Pharmacokinetic Pharmacogenomics. In S. Padmanabhan (Ed.), *Handbook of Pharmacogenomics and Stratified Medicine* (pp. 341–364). Academic Press. (<https://www.sciencedirect.com/science/article/pii/B9780123868824000177>)
- Sandman Z, & Iqbal OA. (2021). *Azithromycin*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK557766/>
- Schiffrin, E. L., Flack, J. M., Ito, S., Muntner, P., & Webb, R. C. (2020). Hypertension and COVID-19. In *American journal of hypertension* (Vol. 33, Issue 5, pp. 373–374). Oxford University Press US.
- Schurink, B., Roos, E., Radonic, T., Barbe, E., Bouman, C. S. C., de Boer, H. H., de Bree, G. J., Bulle, E. B., Aronica, E. M., Florquin, S., Fronczek, J., Heunks, L. M. A., de Jong, M. D., Guo, L., du Long, R., Lutter, R., Molenaar, P. C. G., Neefjes-Borst, E. A., Niessen, H. W. M., ... Bugiani, M. (2020). Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. *The Lancet Microbe*, 1(7), e290–e299. [https://doi.org/10.1016/S2666-5247\(20\)30144-0](https://doi.org/10.1016/S2666-5247(20)30144-0)
- Sekimoto, M., Imai, T., Hidaka, S., Chiba, N., Sakurai, A., Hata, M., & Kikuchi, N. (2022). Elevated INR in a COVID-19 patient after concomitant administration of favipiravir and warfarin: A case report. *Journal of Clinical*

*Pharmacy and Therapeutics*, 47(3), 407–410.  
<https://doi.org/10.1111/jcpt.13499>

Shah, N., & Gossman, W. (2022). Omeprazole. In *StatPearls*.

<https://www.ncbi.nlm.nih.gov/books/NBK539786/>

Singh, A. K., Gupta, R., Ghosh, A., & Misra, A. (2020). Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 14(4), 303–310.

Singhal, T. (2020). A review of coronavirus disease-2019 (COVID-19). *The Indian Journal of Pediatrics*, 87(4), 281–286.

Spanakis, M., Patelarou, A., Patelarou, E., & Tzanakis, N. (2021). Drug interactions for patients with respiratory diseases receiving covid-19 emerged treatments. In *International Journal of Environmental Research and Public Health* (Vol. 18, Issue 21). MDPI.  
<https://doi.org/10.3390/ijerph182111711>

Sur, M., Lopez, MJ., & Baker, MB. (2022). *Oseltamivir*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK539909/>

Surmelioglu, N., & Demirkhan, K. (2020). COVID-19 drug interactions. *Journal of Critical and Intensive Care*, 11, 43–45.  
<https://doi.org/10.37678/dcybd.2020.2409>

Susilo, A., Martin Rumende, C., Pitoyo, C. W., Djoko Santoso, W., Yulianti, M., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Khie Chen, L., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O., & Yunihastuti, E. (2020). TINJAUAN PUSTAKA. In *Jurnal Penyakit Dalam Indonesia* / (Vol. 7, Issue 1). <https://www.ncbi.nlm.nih.gov/nuccore/>

Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., Lu, P., Venkataraman, A., Park, A., Liu, F., Meir, A., Sun, J., Wang, E. Y., Casanovas-Massana, A., Wyllie, A. L., ... Iwasaki, A. (2020). Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature*, 588(7837), 315–320.  
<https://doi.org/10.1038/s41586-020-2700-3>

- Talreja, O., & Cassagnol, M. (2022). *Diltiazem*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK532937/>
- Talreja, O., Kerndt, CC., & Cassagnol, M. (2021). *Simvastatin*. Treasure Island (FL): StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK532919/>
- Talukdar, D., Jain, V., Balaramnavar, V., Srivastava, S. P., Sivanandy, P., & Gupta, M. M. (2021). *Potential Drugs for COVID-19 Treatment Management With Their Contraindications and Drug-Drug Interaction*.
- Tan, Q., Duan, L., Ma, Y. L., Wu, F., Huang, Q., Mao, K., Xiao, W., Xia, H., Zhang, S., Zhou, E., Ma, P., Song, S., Li, Y. M., Zhao, Z., Sun, Y., Li, Z., Geng, W., Yin, Z., & Jin, Y. (2020). Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. *Bioorganic Chemistry*, 104. <https://doi.org/10.1016/j.bioorg.2020.104257>
- Tatro D. (2006). *Drug Interaction Facts TM* (D. Tatro, Ed.). St. Louis, Missouri.
- Telbisz, Á., Ambrus, C., Mózner, O., Várady, G., Bakos, É., Sarkadi, B., & Özvegy-Laczka, C. (2021). Interactions of anti-COVID-19 drug candidates with multispecific ABC and OATP drug transporters. *BioRxiv*. <https://doi.org/10.1101/2020.11.21.392555>
- Tolbert, D., & Larsen, F. (2019). A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam. In *Journal of Clinical Pharmacology* (Vol. 59, Issue 1, pp. 7–19). Blackwell Publishing Inc. <https://doi.org/10.1002/jcph.1313>
- Uptodate. (2022). *Lexi-Interact: Lexicomp Interaction Checker*. [https://www.uptodate.com/drug-interactions/?source=responsive\\_home#di-druglist](https://www.uptodate.com/drug-interactions/?source=responsive_home#di-druglist)
- Uwai, Y. (2018). Enantioselective drug recognition by drug transporters. *Molecules*, 23(12), 3062.
- Välitalo, P. A., Kemppainen, H., Kulo, A., Smits, A., van Calsteren, K., Olkkola, K. T., de Hoon, J., Knibbe, C. A. J., & Allegaert, K. (2017). Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. *British Journal of Clinical Pharmacology*, 83(9), 1966–1975. <https://doi.org/10.1111/bcp.13311>

- Veiga-Matos, J., Remião, F., & Motaes, A. (2020). Pharmacokinetics and toxicokinetics roles of membrane transporters at kidney level. *Journal of Pharmacy & Pharmaceutical Sciences*, 23, 333–356.
- Vrachatis, D. A., Papathanasiou, K. A., Giotaki, S. G., Iliodromitis, K. E., Papaioannou, T. G., Stefanini, G. G., Cleman, M., Siasos, G., Reimers, B., Lansky, A., Tardif, J. C., Deftereos, S. G., & Giannopoulos, G. (2021). Repurposing colchicine's journey in view of drug-to-drug interactions. A review. *Toxicology Reports*, 8, 1389–1393. <https://doi.org/10.1016/j.toxrep.2021.07.009>
- Wessler, J. D., Grip, L. T., Mendell, J., & Giuglano, R. P. (2013). The P-glycoprotein transport system and cardiovascular drugs. In *Journal of the American College of Cardiology* (Vol. 61, Issue 25, pp. 2495–2502). <https://doi.org/10.1016/j.jacc.2013.02.058>
- WHO. (2022). *WHO Coronavirus Disease (COVID-19) Dashboard*. <https://covid19.who.int/> diakses 16 Juni 2022.
- Widjaja, J. T., Kwee, L., Giantara, A. K., Suabgiyo, H. A., Edwin, C., & Putri, R. L. (2021). Karakteristik Pasien COVID-19 Rawat Inap di RS Immanuel Bandung, Indonesia. *Journal Of Medicine And Health*, 3(2).
- Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Snead, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016). Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement from the American Heart Association. *Circulation*, 134(21), e468–e495. <https://doi.org/10.1161/CIR.000000000000456>
- Wile, D. (2012). Diuretics: A review. In *Annals of Clinical Biochemistry* (Vol. 49, Issue 5, pp. 419–431). <https://doi.org/10.1258/acb.2011.011281>
- Wu, Y. C., Chen, C. S., & Chan, Y. J. (2020). The outbreak of COVID-19: An overview. *Journal of the Chinese Medical Association*, 83(3), 217–220. <https://doi.org/10.1097/JCMA.0000000000000270>
- Yang, Y., Li, P., Zhang, Z., Wang, Z., Liu, L., & Liu, X. (2020). Prediction of cyclosporin-mediated drug interaction using physiologically based pharmacokinetic model characterizing interplay of drug transporters and

- enzymes. *International Journal of Molecular Sciences*, 21(19), 1–27. <https://doi.org/10.3390/ijms21197023>
- Zhao, Y., Harmatz, J. S., Epstein, C. R., Nakagawa, Y., Kurosaki, C., Nakamura, T., Kadota, T., Giesing, D., Court, M. H., & Greenblatt, D. J. (2015). Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. *British Journal of Clinical Pharmacology*, 80(5), 1076–1085. <https://doi.org/10.1111/bcp.12644>
- Zhou, S. (2018). *Cytochrome P450 2D6: Structure, Function, Regulation, and Polymorphism*. CRC Press.
- Zhou, Y.-W., Xie, Y., Tang, L.-S., Pu, D., Zhu, Y.-J., Liu, J.-Y., & Ma, X.-L. (2021). Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. *Signal Transduction and Targeted Therapy*, 6(1), 1–25.
- Zulkarnaini, A., & Martini, R. D. (2019). Gambaran Polifarmasi Pasien Geriatri Dibeberapa Poliklinik RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*, 8(1S), 1–6.

